Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes - Trial NCT06339086
Access comprehensive clinical trial information for NCT06339086 through Pure Global AI's free database. This Phase 3 trial is sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 478 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chengdu Brilliant Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 3
Apr 01, 2024
Dec 30, 2025
Primary Outcome
Change in HbA1c
Summary
The goal of this clinical trial is to evaluate the similarities in efficacy and safety of
 semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic
 control after metformin treatment.
 
 Participants will receive either a dose of semaglutide or Ozempic® once weekly (subcutaneous
 injection) as add-on to metformin for 32 weeks.
 
 Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the
 efficacy, safety, pharmacokinetics, and immunogenicity of them are similar.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06339086
Non-Device Trial